The U.S. Food and Drug Administration has approved Halaven for advanced liposarcoma, a type of soft tissue cancer. As the first chemotherapy drug shown to improve survival, Halaven was administered to 140 patients with liposarcoma in clinical studies; average survival period was 15.6 months compared to 8.4 months for those who were administered another chemotherapy drug.
To read more about this study, click here.
No comments:
Post a Comment